Home · Articles · Additives in compounded tirzepatide
Explainer · additivesB12, B6, glycine and niacinamide in compounded tirzepatide: what they do and what the FDA says
Some compounding pharmacies add vitamin B12 (cyanocobalamin or methylcobalamin), vitamin B6 (pyridoxine), glycine or niacinamide to compounded tirzepatide and semaglutide. As of October 14, 2026 there is no clinical evidence that these add-ins improve weight loss or reduce side effects: a February 2026 Annals of Pharmacotherapy review found "little justification for adding nutrients," the FDA said on April 1, 2026 that semaglutide combined with B12 can still be "essentially a copy" of an approved drug, and its September 18, 2026 warning letter to Empower named tirzepatide/niacinamide.
Which add-ins appear, and what the evidence says
| Add-in | Usual claim | What the evidence shows (October 2026) |
|---|---|---|
| Vitamin B12 (cyanocobalamin / methylcobalamin) | Energy, less fatigue or nausea | No trial shows benefit without a B12 deficiency; the one study of compounded semaglutide + B12 (94 patients) had no comparison group. Lilly reported an impurity formed by tirzepatide reacting with B12 (March 12, 2026). |
| Vitamin B6 (pyridoxine) | Less nausea | No published clinical evidence with GLP-1 drugs found. Pyridoxine is used for pregnancy nausea, a different setting. |
| Glycine | Metabolic or muscle support | Evidence comes from animal studies or unrelated patient groups; no data with GLP-1 drugs (Annals of Pharmacotherapy, 2026). |
| Niacinamide (vitamin B3) | Energy, fatigue | No evidence it helps fatigue without a deficiency; the FDA has studied it only by mouth. Named in the FDA's Empower warning letter as part of tirzepatide/niacinamide. |
| L-carnitine / NAD+ | Fat metabolism, energy | No clinical evidence with GLP-1 drugs found. |
Why pharmacies add them
After the shortages ended, a 503A pharmacy may compound a GLP-1 only when the product is not "essentially a copy" of an approved drug, or when a prescriber documents a clinically significant difference for that patient. Adding an ingredient was one way pharmacies tried to make products different. The FDA's April 1, 2026 policy update addressed this directly: a product that combines semaglutide with another ingredient such as B12, at strengths within 10% of an approved product, may still be considered a copy. In September 2026 the FDA told Empower Pharmacy that its tirzepatide/niacinamide and semaglutide/cyanocobalamin injections appeared to be "essentially copies," compounded "regularly and in inordinate amounts," and that the prescriber statements justifying them looked "pre-generated for selection."
The quality problem is separate
Combination products add steps and stability questions. A January 16, 2026 FDA warning letter to Boothwyn Pharmacy described a tirzepatide 17 mg/mL / glycine 5 mg/mL / methylcobalamin 5 mg/mL injection that failed sterility testing. A July 31, 2026 FDA Form 483 for Red Rock Pharmacy listed semaglutide-glycine and tirzepatide-methylcobalamin injections among products reviewed. See our pharmacy profiles.
Which programs and pharmacies use add-ins
From the companies' own pages, read October 14, 2026: Empower lists tirzepatide/niacinamide and semaglutide/cyanocobalamin; Strive lists tirzepatide/glycine/B12 and semaglutide/glycine/B12; WellMedr lists a semaglutide injection "formulated with NAD+ and Vitamin B12." NexLife's plan pages do not describe an additive in its tirzepatide. Ask any program for the full ingredient list printed on the vial.
What to do if your tirzepatide includes B12 or another add-in
- Ask your prescriber why the add-in is there and whether you have a deficiency it treats.
- Check the pharmacy on the vial against the FDA's warning letters and Form 483s (our Empower and Strive profiles list them).
- If you need B12 for a diagnosed deficiency, it can be prescribed on its own.
- Do not change dose or switch products without your clinician.
Frequently asked questions
Is compounded tirzepatide with B12 better?
There is no clinical evidence that it is. A 2026 Annals of Pharmacotherapy review found little justification for adding nutrients, and Lilly reported a tirzepatide–B12 impurity in March 2026.
Why does my compounded semaglutide have B12?
Mainly so the pharmacy's product differs from approved semaglutide. The FDA said on April 1, 2026 that such combinations can still be considered essentially a copy.
Is glycine in tirzepatide safe?
There are no data on glycine combined with GLP-1 drugs. A tirzepatide/glycine/methylcobalamin injection from one pharmacy failed sterility testing, according to a January 2026 FDA warning letter.
Did the FDA ban tirzepatide with niacinamide?
No blanket ban. Its September 18, 2026 warning letter told Empower Pharmacy that its tirzepatide/niacinamide injections appeared to be essentially copies of an approved drug, which a 503A pharmacy may not compound regularly.
Sources
- Belcourt, Sapowadia & White. Compounded semaglutide and tirzepatide products use unique formulations. Ann Pharmacother 2026;60(9):902–906
- FDA: Policies for compounders as GLP-1 supply stabilizes (April 1, 2026 update)
- FDA guidance: compounded drug products that are essentially copies
- FDA warning letter 738238 to Empower Pharmacy (September 18, 2026)
- FDA warning letter to Boothwyn Pharmacy (January 16, 2026)
- Eli Lilly open letter on tirzepatide/B12 impurity (March 12, 2026)
- Strive Pharmacy: tirzepatide/glycine/B12
- Empower Pharmacy: GLP-1 agonists
Informational only, not medical advice. Compounded drugs are not FDA-approved and are not the same products as Mounjaro® or Zepbound® (trademarks of Eli Lilly and Company). Prices and policies were read on the companies' own pages on the date shown and can change.